Cargando…
Human cerebral organoids as a therapeutic drug screening model for Creutzfeldt–Jakob disease
Creutzfeldt–Jakob Disease (CJD) is a fatal, currently incurable, neurodegenerative disease. The search for candidate treatments would be greatly facilitated by the availability of human cell-based models of prion disease. Recently, an induced pluripotent stem cell derived human cerebral organoid mod...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7943797/ https://www.ncbi.nlm.nih.gov/pubmed/33727594 http://dx.doi.org/10.1038/s41598-021-84689-6 |
_version_ | 1783662567829274624 |
---|---|
author | Groveman, Bradley R. Ferreira, Natalia C. Foliaki, Simote T. Walters, Ryan O. Winkler, Clayton W. Race, Brent Hughson, Andrew G. Zanusso, Gianluigi Haigh, Cathryn L. |
author_facet | Groveman, Bradley R. Ferreira, Natalia C. Foliaki, Simote T. Walters, Ryan O. Winkler, Clayton W. Race, Brent Hughson, Andrew G. Zanusso, Gianluigi Haigh, Cathryn L. |
author_sort | Groveman, Bradley R. |
collection | PubMed |
description | Creutzfeldt–Jakob Disease (CJD) is a fatal, currently incurable, neurodegenerative disease. The search for candidate treatments would be greatly facilitated by the availability of human cell-based models of prion disease. Recently, an induced pluripotent stem cell derived human cerebral organoid model was shown to take up and propagate human CJD prions. This model offers new opportunities to screen drug candidates for the treatment of human prion diseases in an entirely human genetic background. Here we provide the first evidence that human cerebral organoids can be a viable model for CJD drug screening by using an established anti-prion compound, pentosan polysulfate (PPS). PPS delayed prion propagation in a prophylactic-like treatment paradigm and also alleviated propagation when applied following establishment of infection in a therapeutic-like treatment paradigm. This study demonstrates the utility of cerebral organoids as the first human 3D cell culture system for screening therapeutic drug candidates for human prion diseases. |
format | Online Article Text |
id | pubmed-7943797 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-79437972021-03-10 Human cerebral organoids as a therapeutic drug screening model for Creutzfeldt–Jakob disease Groveman, Bradley R. Ferreira, Natalia C. Foliaki, Simote T. Walters, Ryan O. Winkler, Clayton W. Race, Brent Hughson, Andrew G. Zanusso, Gianluigi Haigh, Cathryn L. Sci Rep Article Creutzfeldt–Jakob Disease (CJD) is a fatal, currently incurable, neurodegenerative disease. The search for candidate treatments would be greatly facilitated by the availability of human cell-based models of prion disease. Recently, an induced pluripotent stem cell derived human cerebral organoid model was shown to take up and propagate human CJD prions. This model offers new opportunities to screen drug candidates for the treatment of human prion diseases in an entirely human genetic background. Here we provide the first evidence that human cerebral organoids can be a viable model for CJD drug screening by using an established anti-prion compound, pentosan polysulfate (PPS). PPS delayed prion propagation in a prophylactic-like treatment paradigm and also alleviated propagation when applied following establishment of infection in a therapeutic-like treatment paradigm. This study demonstrates the utility of cerebral organoids as the first human 3D cell culture system for screening therapeutic drug candidates for human prion diseases. Nature Publishing Group UK 2021-03-09 /pmc/articles/PMC7943797/ /pubmed/33727594 http://dx.doi.org/10.1038/s41598-021-84689-6 Text en © This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Groveman, Bradley R. Ferreira, Natalia C. Foliaki, Simote T. Walters, Ryan O. Winkler, Clayton W. Race, Brent Hughson, Andrew G. Zanusso, Gianluigi Haigh, Cathryn L. Human cerebral organoids as a therapeutic drug screening model for Creutzfeldt–Jakob disease |
title | Human cerebral organoids as a therapeutic drug screening model for Creutzfeldt–Jakob disease |
title_full | Human cerebral organoids as a therapeutic drug screening model for Creutzfeldt–Jakob disease |
title_fullStr | Human cerebral organoids as a therapeutic drug screening model for Creutzfeldt–Jakob disease |
title_full_unstemmed | Human cerebral organoids as a therapeutic drug screening model for Creutzfeldt–Jakob disease |
title_short | Human cerebral organoids as a therapeutic drug screening model for Creutzfeldt–Jakob disease |
title_sort | human cerebral organoids as a therapeutic drug screening model for creutzfeldt–jakob disease |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7943797/ https://www.ncbi.nlm.nih.gov/pubmed/33727594 http://dx.doi.org/10.1038/s41598-021-84689-6 |
work_keys_str_mv | AT grovemanbradleyr humancerebralorganoidsasatherapeuticdrugscreeningmodelforcreutzfeldtjakobdisease AT ferreiranataliac humancerebralorganoidsasatherapeuticdrugscreeningmodelforcreutzfeldtjakobdisease AT foliakisimotet humancerebralorganoidsasatherapeuticdrugscreeningmodelforcreutzfeldtjakobdisease AT waltersryano humancerebralorganoidsasatherapeuticdrugscreeningmodelforcreutzfeldtjakobdisease AT winklerclaytonw humancerebralorganoidsasatherapeuticdrugscreeningmodelforcreutzfeldtjakobdisease AT racebrent humancerebralorganoidsasatherapeuticdrugscreeningmodelforcreutzfeldtjakobdisease AT hughsonandrewg humancerebralorganoidsasatherapeuticdrugscreeningmodelforcreutzfeldtjakobdisease AT zanussogianluigi humancerebralorganoidsasatherapeuticdrugscreeningmodelforcreutzfeldtjakobdisease AT haighcathrynl humancerebralorganoidsasatherapeuticdrugscreeningmodelforcreutzfeldtjakobdisease |